A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Atorvastatin for Nephrogenic Diabetes Insipidus in Lithium-Users
- Fotso Soh, Jocelyn
- Beaulieu, Serge
- Trepiccione, Francesco
- Linnaranta, Outi
- Torres-Platas, Gabriela
- Platt, Robert W
- Renaud, Suzane
- Su, Chien-Lin
- Mucsi, Istvan
- D'Apolito, Luciano
- Mulsant, Benoit H
- Levinson, Andrea
- Saury, Sybille
- Müller, Daniel
- Schaffer, Ayal
- Dols, Annemiek
- Low, Nancy
- Cervantes, Pablo
- Christensen, Birgitte M
- Herrmann, Nathan
- Rajji, Tarek
- Rej, Soham
DOIAbstract
Lithium remains an important treatment for mood disorders but is associated with kidney disease. Nephrogenic diabetes insipidus (NDI) is associated with up to 3-fold risk of incident chronic kidney disease amongst lithium users. There is limited randomized controlled trials (RCT) for treatments of lithium-induced NDI, and existing therapies can be poorly tolerated. Therefore, novel treatments are needed for lithium-induced NDI
Add to ORKG